Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine ...

ADHD is a common behavioral condition that affects approximately 7 million US children, including about a million kids ...

Hi, it’s Ike in Boston. We’ve gotten some more insight into the ADHD drug shortages, which have been going on for over two years. But first ... Attention deficit hyperactivity disorder ...

Thomas was seeking alternative treatment for ADHD and sleep apnoea, where he underwent hyperbaric oxygen therapy. This ...

Amlodipine, a blood pressure drug, shows promise in reducing ADHD symptoms by targeting brain calcium channels. Repurposing ...

ADHD prescriptions in England have surged 18% annually since the pandemic, highlighting a major shift in diagnosis and ...

A decade-spanning study has revealed a troubling side effect when pregnant women take a common painkiller during their ...

Prescriptions for attention deficit hyperactivity disorder (ADHD) in England have risen 18% year on year since the pandemic.

A study of people who started ADHD stimulant treatment via telehealth vs in-person visits shows no difference in risk of new substance use disorders except for young adults age 26-34.

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has ...

The Food and Drug Administration first announced a shortage of Adderall, the drug most commonly used to treat ADHD, in ...

Opens in a new tab or window Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine due to the presence of a possible carcinogen.